Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.
Marjan Ghiti MoghadamHarald E VonkemanPeter M Ten KloosterJanneke TekstraDirkjan van SchaardenburgMirian Starmans-KoolElisabeth BrouwerReinhard BosWillem F LemsEdgar M ColinCornelia F AllaartInger L MeekRobert LandewéHein J Bernelot MoensPiet L C M van RielMart A F J van de LaarTim L Jansennull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2017)
Stopping TNFi treatment results in substantially more flares than does continuation of TNFi in patients with established RA in remission or with stable low disease activity.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- randomized controlled trial
- juvenile idiopathic arthritis
- study protocol
- open label
- interstitial lung disease
- clinical trial
- systematic review
- radiation therapy
- phase ii
- double blind
- systemic sclerosis